modelRezafunginAcetate_Roepcke2023_reference

Extends from Pharmacolibrary.Pharmacokinetic.Models.PK_1C.

Information

name:rezafungin_acetate
ATC code:J02AX08
model:one compartment, IV dosing (PK_1C)
source:Roepcke S et al. 2023
population:healthy volunteers and patients with candidemia/invasive candidiasis
measured compound:rezafungin
review:accepted with caveats
record page:pharmacolibrary-docs

Parameters as reported in the paper

parametervalueunitmeaning
CL2.77L/hCL
theta_cl_category9.25equation variable
V13.96LV
Q25.38L/hQ
Q34.37L/hQ3
theta_q319_weight_power16.4equation variable
theta_q319_weight_power9.47equation variable
theta_v1_category18.1equation variable
theta_q319_weight_power11.4equation variable
theta_q319_weight_power14.9equation variable

About rezafungin_acetate

Rezafungin acetate is an antifungal medicine used to treat invasive candida infections of the bloodstream. It is a newer antifungal that has been authorised in the United States but is not approved in the European Union.

Unverified — written by glm-5.3-flash from general knowledge (no Wikidata entry found) and the WHO ATC classification; not checked by a person.

References

  1. Roepcke S et al. (2023). Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis. Antimicrobial agents and chemotherapy 67(12):e0091623. DOI:10.1128/aac.00916-23 PUBMED:38014945

Parameters

TypeNameDefaultDescription
RealCl_ref7.694444444444444e-07Cl [m3/s]
Booleancov_category_0falsecategory level 0
RealVd_ref0.00396Vd [m3]
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.0009Volume of distribution per kg (default 0.9 L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)1bioavailability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)2.7777777777777776e-7clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1e-4administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Info › Therapeutic range (metadata, not used in equations)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008maximal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Info › Substance metadata
Modelica.Units.SI.MolarMassMM (from PK_1C)0molar mass [kg/mol]; 0 = not supplied (molar concentrations are then 0)
Info › Substance metadata (not used in equations)
Pharmacolibrary.Types.DoseLD50 (from PK_1C)0median lethal dose [mg/kg]; 0 = unknown

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)central-compartment elimination half-life = ln(2)*Vd/Cl (1-compartment approximation; NOT the terminal half-life of 2-/3-compartment models)

Revisions

  • 11/2026 generated by pharmacolibrary-dev export.pharmacolibrary_models from Roepcke_2023: parameters extracted from the paper by the pharmacolibrary-dev pipeline, model built by its engineer, reviewed: accepted with caveats